Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
University of New South Wales, Kensington, NSW, Australia.
Intensive Care Med. 2018 Jul;44(7):1003-1016. doi: 10.1007/s00134-018-5197-6. Epub 2018 May 14.
To assess the effect of low dose corticosteroids on outcomes in adults with septic shock.
We systematically reviewed randomised clinical trials (RCTs) comparing low-dose corticosteroids to placebo in adults with septic shock. Trial selection, data abstraction and risk of bias assessment were performed in duplicate. The primary outcome was short-term mortality. Secondary and tertiary outcomes included longer-term mortality, adverse events, quality of life, and duration of shock, mechanical ventilation and ICU stay.
There were 22 RCTs, including 7297 participants, providing data on short-term mortality. In two low risk of bias trials, the relative risk (RR) of short-term mortality with corticosteroid versus placebo was 0.98 [95% confidence interval (CI) 0.89-1.08, p = 0.71]. Sensitivity analysis including all trials was similar (RR 0.96; 95% CI 0.91-1.02, p = 0.21) as was analysis of longer-term mortality (RR 0.96; 95% CI 0.90-1.02, p = 0.18). In low risk of bias trials, the risk of experiencing any adverse event was higher with corticosteroids; however, there was substantial heterogeneity (RR 1.66; 95% CI 1.03-2.70, p = 0.04, I = 78%). No trials reported quality of life outcomes. Duration of shock [mean difference (MD) -1.52 days; 95% CI -1.71 to -1.32, p < 0.0001], duration of mechanical ventilation (MD -1.38 days; 95% CI -1.96 to -0.80, p < 0.0001), and ICU stay (MD -0.75 days; 95% CI -1.34 to -0.17, p = 0.01) were shorter with corticosteroids versus placebo.
In adults with septic shock treated with low dose corticosteroids, short- and longer-term mortality are unaffected, adverse events increase, but duration of shock, mechanical ventilation and ICU stay are reduced. PROSPERO registration no. CRD42017084037.
评估小剂量皮质类固醇对脓毒性休克成人患者结局的影响。
我们系统地回顾了比较小剂量皮质类固醇与安慰剂治疗脓毒性休克成人患者的随机临床试验(RCT)。试验选择、数据提取和偏倚风险评估均由两人进行。主要结局为短期死亡率。次要和三级结局包括长期死亡率、不良事件、生活质量以及休克、机械通气和 ICU 停留时间。
共有 22 项 RCT,纳入 7297 名患者,提供了短期死亡率数据。在两项低偏倚风险试验中,皮质类固醇与安慰剂相比的短期死亡率的相对风险(RR)为 0.98 [95%置信区间(CI)0.89-1.08,p=0.71]。包括所有试验的敏感性分析结果相似(RR 0.96;95% CI 0.91-1.02,p=0.21),长期死亡率分析结果也相似(RR 0.96;95% CI 0.90-1.02,p=0.18)。在低偏倚风险试验中,皮质类固醇治疗的不良事件风险更高;然而,存在显著的异质性(RR 1.66;95% CI 1.03-2.70,p=0.04,I=78%)。没有试验报告生活质量结局。休克持续时间[平均差(MD)-1.52 天;95% CI -1.71 至-1.32,p<0.0001]、机械通气时间(MD -1.38 天;95% CI -1.96 至-0.80,p<0.0001)和 ICU 停留时间(MD -0.75 天;95% CI -1.34 至-0.17,p=0.01)均缩短。
在接受小剂量皮质类固醇治疗的脓毒性休克成人患者中,短期和长期死亡率不受影响,不良事件增加,但休克、机械通气和 ICU 停留时间缩短。PROSPERO 注册号 CRD42017084037。